This spring, Clubs from all over the world are coming together
We have the opportunity to help raise funds to support Augie’s Quest to cure ALS through this global fundraiser. Please join us! This six-week challenge is the perfect excuse to get ready for summer while doing good. Plus there are over $50k in prizes to be given away including fitness equipment, vacation packages, experiences, and so much more!
Thank you to RVC members and staff that participated!
Emily Cleaveland
Kory Cazeault
Sherry Edmonds
Fariha Chaudhry
20,161 total MEPs earned, ranking her #10 in the WORLD for most MEPs.
KateR
Alan R
CathS
CathyP
Chazard
DanN
CrzyEm
gentle
JK
AJH
JP
SpinDr
BamBam
1968
keewee
kq
KBYEEE
🙂
Gaisce
DaniellD
DDG
ElizaA
NY JAY
PhillyJo
Brooke
MAN
CLA
ChloeW
KEL
NatSte
PauPel
ABB36
-#robean
Amy40er
Winks
mama
TerryH
TimR
valerina
AmaliM
Coach K
Travic
ClintonA
LizH
JohnGrai
JDS
Lulu
LSG
kl2510
pl
LAS
LLF
ROC
When/What
- May 1 – June 18
- A crucial ALS treatment called AT-1501 is currently in development. Myzone and Augie’s Quest are partnering with you to raise funds to help bring this potentially life-saving drug one step closer to reality
- All funds donated go directly to the ALS/TDI Research Center in Cambridge, Massachusetts
How
- Get your MYZONE belt from the FITshop for only $65 ($99 value)
- Register here or ask staff for details
- Join the Challenge by donating $15.01
- Earn 1501 MEPS and enter into the raffle to win prizes valued at over $50k
- An extra ticket will be awarded for every 100 MEPs earned after 1,501. That’s 35 chances to win!
Why
- Be a Difference Maker for those impacted with ALS
- Help in securing the funds to complete the job on getting AT-1501 into the important Clinical trials with people suffering with ALS
- Provide HOPE for those with ALS who are looking to us to help them in their fight against ALS
What is AT-1501?
ALS/TDI; officially known as The ALS Therapy Development Institute has been working with their passionate research team developing AT-1501 since 2013. Currently, it is being evaluated for safety towards humans. To move AT-1501 through a Phase 2 clinical trial, we will need to raise $30,000,000.
AT-1501 has produced the most exciting outcomes since the inception of ALS/TDI. According to Steve Perrin, Ph.D, CEO/CSO, AT-1501 is the most effective potential treatment tested for ALS. It has shown in lab tests to achieve the following outcomes:
- Extended Life Span Significantly
- Delayed Disease onset
- Improved Body Weight, signaling that muscle is healthier
- Improved the percentage of neuro-muscular junctions allowing muscles to remain functional
- Decreased indications of inflammation in nerves and spinal cord
AT-1501 is an antibody with therapeutic and promising preclinical data. It blocks specific immune cell activation and may protect nerves against the progression of ALS.
